<DOC>
	<DOCNO>NCT02011711</DOCNO>
	<brief_summary>Clinical study determine hormonal contraceptive use effect cell fight infection ( i.e. , immune cell ) .</brief_summary>
	<brief_title>Modulation Immunity Hormonal Contraceptives</brief_title>
	<detailed_description>Feminization HIV pandemic impetus well understanding risk factor promote male female sexual transmission . One putative risk factor hormonal contraceptive use . Our laboratory recently report dendritic cell activation , virus-specific T cell expansion , memory T cell development impair among female mouse administer depot-medroxyprogesterone acetate ( DMPA ) prior viral infection mucosal tissue , enrol woman clinical investigation explore immunomodulatory effect several common hormonal contraceptive form . Completion research provide important comparative evaluation capacity drug modulate host defense combat genital tract infection , eventually supply healthcare provider inform recommendation regard appropriate hormonal contraceptive choice among woman risk acquisition HIV .</detailed_description>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>pregnant regular menstrual cycle use oral contraceptive Mirena 3 month prior enrollment use depotmedroxyprogesterone acetate 6 month prior enrollment diagnosis sexually transmit infection 30 day prior enrollment history cervical malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>